Although it is necessary to wait for the results of several ongoing clinical trials using immune checkpoint inhibitors such as nivolumab, ipilimumab, and durvalumab (anti-PD-L1 antibody), immune checkpoint inhibition can be a novel strategy to treat advanced MF/SS. Here, CD274 is linked to synovial sarcoma.